Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Konan Medical has launched its ObjectiveField visual field analyzer in the US. The ObjectiveField is an objective perimeter designed to detect visual field abnormalities using pupillary responses. ...
Nevada-based Avant Technologies and Ainnova Tech, of Houston, Texas, announced Nov. 20 that the two companies would advance Ainnova’s proprietary low-cost retinal camera packaged with the Vision AI...
Five Medicare administrative contractors have issued their final coverage policies for minimally invasive glaucoma surgery, or MIGS, along with more technical billing and coding documents. The poli...
France’s Nicox announced Nov. 19 that it had chosen the higher dose of NCX 470 ophthalmic solution to advance in the Phase III Mont Blanc trial in glaucoma. The company said both doses tested—0.065...
The Centers for Medicare and Medicaid Services (CMS) published on Nov. 1 the final schedule of Medicare reimbursement fees for physicians in 2025. It also released its facility fee payments for ASC...
Harrow’s ImprimisRx subsidiary received a $34.9 million verdict on Nov. 20, 2024, in a trademark infringement lawsuit against OSRX Pharmaceuticals, of Missoula, Montana. OSRX is an affiliate of Ocu...
Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...
EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $161 million upsized underwritten public offering. Proceeds in part will fund clinical development of Duravyu. Financing an...
Recent studies indicate that up to 6 percent of the US population is currently taking a GLP-1 receptor agonist, a class of drugs prescribed to help manage blood glucose levels for diabetes and weig...
New glaucoma lasers and surgical devices were shown at various venues during the 2024 AAO meeting, including Glaucoma Subspecialty Day and the Eyecelerator meeting. There was also an important upda...
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...
AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...
Los Angeles-based Spinogenix reported Oct. 16 that it was launching a program to evaluate SPG302 as a potential neuroprotective therapeutic for glaucoma. Spinogenix describes SPG302 as a once-a-day...
France’s Nicox announced Oct. 14 a deal with Soleus Capital under which Soleus will acquire Nicox’ royalties from the glaucoma treatment Vyzulta for $15 million, while providing $1.5 million in equ...
Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...
The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in September 2024, according to the agency’s database. Zeiss gained clearance for its combination Y...
Rick Lewis, MD, chief medical officer at ViaLase, provided an update at the 2024 ESCRS congress on the ViaLuxe glaucoma laser, including the system’s most recent clinical trial results. The ViaLuxe...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...
Finland’s iCare, a subsidiary of Revenio Group, has launched its iCare ST500 rebound tonometer that can be attached to a slit lamp. The device gained US FDA 510(k) clearance on Sept. 27. The compan...
Iridex reported Oct. 3 that it had appointed Patrick Mercer as chief executive officer, to go along with his role as president, effective Oct. 1. Mercer had also served as the company’s chief opera...
Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...
France’s Nicox announced Sept. 23 that it had signed an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5...
Ripple Therapeutics, of Toronto, Canada, announced Sept. 17 that it had signed a collaboration agreement with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral bimatop...
US ophthalmologists reported that ophthalmic procedures increased 0.5 percent in Q2-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...
Injectsense, of Emeryville, California, announced Aug. 27 that it had implanted its first ultraminiature wireless sensor for measuring intraocular pressure (IOP). Glaucoma specialist Juan Mura, MD,...
Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...
Bausch + Lomb is working with Goldman Sachs to explore a sale of the company, the Financial Times reported Sept. 14, with private equity the most likely buyer. The move is being evaluated as a way ...
Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset, along with standard automated perimetry. The German ophthalmic diagnosti...
Belgium’s iStar Medical announced Sept. 4 that it had appointed Richard Beckman, MD, as chief medical officer and member of the company’s board. Beckman most recently served as CMO of Adverum Biote...
Injectsense, of Emeryville, California, announced Aug. 27 that it had implanted its first ultraminiature wireless sensor for measuring intraocular pressure (IOP). Glaucoma specialist Juan Mura, MD,...
Finland’s Revenio Group announced Aug. 20 that its iCare subsidiary had assumed ownership of the Dutch artificial intelligence (AI) software company Thirona Retina. iCare had made a minority invest...
Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...
Environmental sustainability programs have grown in scope over the last five years, with major ophthalmic surgery associations joining forces to propose specific actions to reduce the carbon footpr...
ViaLase announced July 30 that the European Union had granted CE marking for its ViaLase Laser for the treatment of adults with primary open-angle glaucoma. The system uses an OCT-guided femtosecon...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...
AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....
Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...
Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...
ViaLase announced July 30 that the European Union had granted CE marking for its ViaLase Laser for the treatment of adults with primary open-angle glaucoma. The system uses an OCT-guided femtosecon...
Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...
Germany’s TME Pharma, a clinical-stage cancer company, announced July 22 that it planned to spin off its asset NOX-E36 to advance it for eye disease. NOX-E36 is an L-stereoisomer RNA aptamer inhibi...
The goal of a growing number of companies entering the already crowded glaucoma device market is to provide surgical treatment options with greater safety and effectiveness. Thirty-six products are...
Balance Ophthalmics has gained US FDA de novo classification for its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, a goggles and pump system designed to lower intraocular pressure (IOP) i...
The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in June 2024, according to the agency’s database. Alcon gained clearance for its much-anticipated ...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Balance Ophthalmics has gained US FDA de novo classification for its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, a goggles and pump system designed to lower intraocular pressure (IOP) i...
US ophthalmologists reported that ophthalmic procedures decreased 6.0 percent in Q1-2024 compared with the same quarter in 2023, according to Market Scope’s latest survey. Year-over-year performanc...
Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...
The US FDA granted six clearances through the ophthalmic device division using the 510(k) pathway in May 2024, according to the agency’s database. Reichert gained market clearance for its new hand-...
Surgeons and ophthalmic societies worked together at open meetings in June to address five Medicare administrative contractors’ latest proposal to limit coverage of minimally invasive glaucoma surg...
Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...
Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...
Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...
Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas optical coherence tomography (OCT) system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlin...
Five Medicare administrative contractors have proposed new limits to their coverage of minimally invasive glaucoma surgery (MIGS). The move comes a year after the same MACs roiled the glaucoma subs...
AbbVie, of North Chicago, Illinois, reported April 26 that its Q1-2024 eye care net revenue totaled $538 million, an 11.7 percent decline (-10.4 percent cc) from $608 million in Q1-2023. Restasis r...
New World Medical reported May 22 that its Kahook Dual Blade Glide (KDB Glide) had gained US FDA 510(k) clearance. The KDB Glide was previously classified as a Class 1, 510(k)-exempt device. With t...
Reichert announced May 6 that its Tono-Vera hand-held tonometer is now available in the US. Tono-Vera provides quick, automated, and reliable intraocular pressure measurements with rebound tonomete...
Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...
RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Artificial intelligence was a prominent topic at the 2024 ARVO meeting. Discussions ranged from using AI in published ophthalmic research to employing it in early detection and monitoring of eye di...
The Weisenfeld and Cogan awards and lectures at the 2024 ARVO meeting put a spotlight on inflammation. Martine Jager, MD, PhD (Netherlands), received the Weisenfeld Award in recognition of her pion...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Sight Sciences, of Menlo Park, California, reported April 29 that it had received a $34 million jury trial verdict in its patent infringement case against Ivantis and acquirer Alcon. The suit, file...
Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...
Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...
Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...
Injectsense announced May 6 that the ethics committee at the Centro de la Vision Clinic in Santiago, Chile, has approved a 20-patient study of the company’s ultra-miniature wireless sensor, designe...
Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...
Sight Sciences, of Menlo Park, California, reported April 29 that ithad received a $34 million jury trial verdict in its patent infringement case against Ivantis and acquirer Alcon. The suit, filed...
Swiss company Roche reported April 24 that Vabysmo sales in Q1-2024 were CHF 847 million ($926.5 million, calculated April 24, 2024), up from CHF 432 million (US $487 million) in Q1-2023. Vabysmo r...
The National Eye Institute (NEI) announced April 8 that researchers from the Medical College of Georgia at Augusta University had established a database of the proteins found in the eye’s aqueous h...
Allergan and Novartis replaced Merck and Pfizer at the top of the glaucoma pharmaceuticals market a decade ago. Now it could be their turn to pass the baton. Allergan, acquired by AbbVie in 2020 an...
The Centers for Medicare and Medicaid Services (CMS) has issued J-codes for Glaukos’ iDose, Regeneron’s Eylea HD, and Astellas Pharma’s Izervay. The code for iDose takes effect July 1, 2024, while ...
Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...
Constance Okeke, MD, is helping to clear the confusion that can come from having multiple choices. “There are so many medicines coming into glaucoma that it can be difficult for a clinician to know...
Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...
Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...
Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...
The Centers for Medicare and Medicaid Services (CMS) has issued a J-code for Glaukos’ iDose. The billing code takes effect July 1, 2024. iDose TR gained US FDA approval under the 505(b)(2) pathway ...
France’s Nicox announced that it had appointed Gavin Spencer, PhD, as chief executive officer, effective Feb. 28. Spencer was most recently executive vice president, chief business officer, and hea...
Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...
----- Refractive: -12.1 IOL: 5.4 Glaucoma: 4.8 Retina: -4.4 ----- US ophthalmologists reported that ophthalmic procedures decreased 1.8 percent in Q4-2023 compared with the same quarter in 2022, ac...
Israel-based CorNeat Vision announced Feb. 27 that it had launched its EverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first syn...
The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in February 2024, according to the agency’s database. CATS Tonometer received clearance for its ton...
Celanese announced the commercial launch Feb. 29 of Glaukos’ iDose TR intracameral travoprost implant for glaucoma. Celanese, a specialty materials and chemical company based in Dallas, Texas, prod...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Sight Sciences reported March 7 that it generated 2023 total revenue of $81.1 million, an increase of 14 percent over $71.3 million in 2022. Surgical glaucoma revenue in 2023 was $74.3 million, a 1...
Celanese announced the commercial launch Feb. 29 of Glaukos’ iDose TR intracameral travoprost implant for glaucoma. Celanese, a global specialty materials and chemical company based in Dallas, Texa...
Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...
Israel-based CorNeat Vision announced Feb. 27 that it had launched itsEverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first synt...
Innovative diagnostics for glaucoma screening, staging, and management were a highlight of the Glaucoma 360 New Horizons Forum, with several physicians showcasing new approaches to visual field tes...
Sight Sciences announced Feb. 14 that it would launch the Ergo-Series of its Omni system for canaloplasty in Europe at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meetin...
The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in January 2024, according to the agency’s database. Meridian received clearance for three laser mo...
4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...
Ophthalmologist (MD) and optometrist (OD) attendees of the 2024 Glaucoma 360 (G360) meeting demonstrated a record interest in participating in the Ninth Annual G360 Survey powered by Market Scope. ...
Two of ophthalmology’s leading innovators headlined the New Horizons Forum at the Glaucoma 360 meeting. Sean Ianchulev, MD—arguably the most prolific ophthalmic product inventor in the US—led off t...
Attendees of the G360 New Horizons Forum received a detailed breakdown of the battle that the ophthalmic industry collectively waged throughout 2023 to stop proposed limits to Medicare coverage for...
Glaucoma specialist H. Dunbar Hoskins Jr., MD, a longtime executive of the American Academy of Ophthalmology who helped shape the society, died Jan. 27, the AAO reported. Hoskins was 84. He served ...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...
France’s Nicox announced Feb. 8 that it had signed a deal granting Japanese drug company Kowa exclusive Japanese rights to develop and commercialize Nicox’ NCX 470 (0.1% bimatoprost) eye drop for g...
Glaucoma specialist H. Dunbar Hoskins Jr., MD, a longtime executive of the American Academy of Ophthalmology who helped shape the society, died Jan. 27, the AAO reported. Hoskins was 84. He served ...
Johnson & Johnson reported Jan. 23 that its full year 2023 global surgical vision revenue was $1.37 billion, a 4.9 percent increase (+5.8 percent cc) over $1.31 billion in 2022. Revenue was down 1....
Israeli company Belkin Vision reported Dec. 12 that its Eagle laser for glaucoma had gained US FDA 510(k) clearance. The Eagle is intended for use in performing a new automated, noncontact, one-sec...
Glaukos reported Dec. 14 that the US FDA had approved its new drug application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, indicated for the reduction ...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Medicare administrative contractors (MACs) threw the near-term future of the glaucoma device market into turmoil in early 2023 when they challenged the medical necessity of canal-based surgical pro...
Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...
Iridex announced Jan. 11 the US launch of its next-generation Iridex 532 green and Iridex 577 yellow lasers for retina and glaucoma. Iridex, of Mountain View, California, said both lasers include c...
Five Medicare administrative contractors (MACs) have withdrawn and retired final policies that would have stopped Medicare coverage of common minimally invasive glaucoma surgeries in their US juris...
Privately held Visiox Pharmaceuticals reported Dec. 27 that it will gain a listing on the Nasdaq through a merger with PowerUp Acquisition Corp., a special purpose acquisition company (SPAC) based ...
New York-based iHealthScreen announced Dec. 5 that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had approved its iPredict automated AI screening system for early diagnosis of d...
Israeli company Belkin Vision reported Dec. 12 that its Eagle laser for glaucoma had gained US FDA 510(k) clearance. The Eagle is intended for use in performing a new automated, noncontact, one-sec...
Glaukos reported Dec. 14 that the US FDA had approved its new drug application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, indicated for the reduction ...
US ophthalmologists reported that ophthalmic procedures decreased 6.4 percent in Q3-2023 compared with the same quarter in 2022, according to Market Scope’s latest survey. Year-over-year performanc...
US glaucoma specialists have over 20 surgical options to treat their patients, but even more devices are available or in the pipeline outside the US, and their developers could seek FDA approval. M...
Ophthalmic manufacturer revenue in Q3-2023 totaled $11.1 billion. Revenue increased 3.4 percent from the same quarter in 2022 and decreased 2.7 percent from Q2-2023. The total includes Market Scope...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
2023 was a busy year for the US FDA in ophthalmology. Among the 11 drug products approved were the first two therapies in the US to treat geographic atrophy; two new drops for dry eye; and a second...
Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...
France’s Ciliatech revealed on Dec. 5 a new design of its CID (Cilioscleral Interpositioning Device), following the filing of additional patents. Ciliatech says its approach with the CID avoids the...
SpyGlass Pharma announced Dec. 5 that it had appointed Margot Goodkin, MD, PhD, as chief medical officer. Goodkin is a glaucoma fellowship-trained ophthalmologist and biopharmaceutical industry vet...
Japanese drugmaker Santen Pharmaceutical announced Nov. 17 that the European Commission had approved its marketing authorization application for preservative-free Catiolanze (cationic emulsion of l...
EyeBio led recent ophthalmic fundraising efforts with $65 million in Series A funding to continue development of its candidate for retinal disease. Financing announced in the past four weeks totale...
The US FDA granted five clearances through the ophthalmic device division using the 510(k) pathway in October 2023, according to the agency’s database. Heidelberg gained market clearance for its An...
Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Dry Eye: New products kept generating buzz around dry eye. Bausch + Lomb leaned into the promotion of Miebo, the new, first-in-class drug therapy that directly targets tear evaporation. Diagnostic ...
Eyecelerator awarded a total of $45 thousand in prize money to winning pitch challengers at its fall meeting, after emerging companies got a chance to work with accomplished industry veterans to re...
Notable diagnostic innovations showcased at the 2023 meeting of the American Academy of Ophthalmology were Topcon’s Tempo perimeter and Heidelberg Engineering’s Anterion anterior OCT platform. Also...
Five of the seven Medicare administrative contractors (MACs) in the US have issued their final reimbursement plans for minimally invasive glaucoma surgery (MIGS) procedures, confirming that they wo...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...
Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2023—its fiscal year Q2-2023—of ¥33.5 billi...
Regeneron of Tarrytown, New York, reported Nov. 2 that its Q3-2023 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.49 billion, with Eylea HD accou...
Swiss company Roche reported Oct. 19 that Q3-2023 Vabysmo sales were CHF 656 million ($732 million, converted Oct. 19), a 309 percent increase over CHF 173 million in Q3-2022. Vabysmo was approved ...
Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...
Minimally Invasive Glaucoma Surgery (MIGS): The ESCRS highlighted the growing importance of MIGS this year by holding the meeting’s first MIGS master class. Several speakers in other sessions extol...
The therapeutic ophthalmic laser market will experience modest growth in the next five years, as laser manufacturers focus on improving convenience and experience for ophthalmologists and patients....
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Sight Sciences, of Menlo Park, California, has informed its employees that it will cut its workforce of 250 by 25 employees as it awaits a final decision by five of the seven Medicare Administrativ...
Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis with offices in the US and Israel...
Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...
Mati Therapeutics, of Austin, Texas, reported Sept. 12 that it had completed a 10 thousand square foot facility in Bryan, Texas, to manufacture the company’s Evolute sustained drug delivery platfor...
US ophthalmologists reported that ophthalmic procedures decreased 4.9 percent in Q2-2023 compared with the same quarter in 2022, according to Market Scope’s latest survey. Year-over-year performanc...
Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor. The Mountain View, California, ophthalmic laser company said there...
The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in August 2023, according to the agency’s database. RxSight received clearance for a new IOL injec...
The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...
Market Scope estimates that the ophthalmic diagnostic equipment market will generate $3.7 billion in total revenue in 2023, and the market will grow to $4.4 billion by 2028, for a compound annual g...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Apotex announced Sept. 5 that it had launched its generic brimonidine tartrate 0.1% ophthalmic solution in the US. Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of...
The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...
Neurotech Pharmaceuticals reported Sept. 13 that Alex Gorsky had been elected to its board as lead director. Gorsky, former chairman and chief executive officer of Johnson & Johnson, stepped down f...
Apotex announced Sept. 5 that it had launched its generic brimonidine tartrate 0.1% ophthalmic solution in the US. Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of...
Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor for the process. The Mountain View, California, ophthalmic laser co...
Israel’s Tarsier Pharma reported Aug. 23 that its TRS01 (dazdotuftide) eye drops failed to meet the primary inflammation endpoint in a Phase III trial in patients with active noninfectious anterior...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
The Centers for Medicare and Medicaid Services (CMS) is proposing to cut the conversion factor for the Physician Fee Schedule (PFS)—one of four factors used in calculating Medicare payments to doct...
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...
New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...
Alcon reported Aug. 15 that its Q2-2023 net sales totaled $2.4 billion, a 9 percent increase (+12 percent cc) over $2.2 billion in Q2-2022. Surgical net sales for implantables, consumables, and equ...
The Centers for Medicare and Medicaid Services (CMS) is proposing to cut the conversion factor for the Physician Fee Schedule (PFS)—one of four factors used in calculating Medicare payments to doct...
Japan-based Hoya Corporation announced July 31 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2023—the first quarter of its fiscal yea...
New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...
The Missouri University of Science and Technology announced July 31 that one of its professors researching glaucoma treatments was awarded a grant from the National Institutes for Health that will ...
Regeneron, of Tarrytown, New York, reported Aug. 3 that its Q2-2023 US revenue for Eylea was $1.5 billion, a 7 decrease from $1.62 billion in Q2-2022. The company attributed the decline to a lower ...
Amneal Pharmaceuticals announced July 26 that it had submitted an abbreviated new drug application (NDA) to the US FDA for bimatoprost ophthalmic solution 0.01%, a generic version of Lumigan, to tr...
Swiss company Roche reported July 27 that Vabysmo sales for Q2-2023 were CHF 525 million ($606 million, converted July 27, 2023), a nearly 500 percent increase over CHF 88 million in Q2-2022. Roche...
The near-term future of the US glaucoma device market is in the hands of Medicare administrative contractors (MACs) after increased use of minimally invasive glaucoma surgery (MIGS) procedures led ...
Provocative ideas, controversies, and calls to action were all part of the 10th World Glaucoma Congress in Rome. Thefour-day meeting (June 28-July 1) was the largest World Glaucoma Congress ever, w...
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...
The quest for safer and more effective glaucoma surgery treatments for all stages of glaucoma has expanded significantly over the past several years, and Market Scope looks for continued investment...
Japanese drugmaker Santen announced July 18 that Harrow had acquired US or Canadian commercial rights to seven of Santen’s branded eye drops, while Visiox Pharma had licensed US rights to Omlonti f...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Neurogene led recent ophthalmic fundraising efforts with a $95 million private placement, as it advances its pipeline, including a gene therapy candidate for Batten disease. Funding announced in th...
Lasers: Impressive six-year results for SLT and new lasers fed growing interest in laser therapy for OHT and open-angle glaucoma. Personalized medicine and interventional glaucoma: Whether called “...
Fotis Topouzis, MD, PhD (Greece), gave the World Glaucoma Congress a preview of the European Glaucoma Society’s new guidelines for minimally invasive glaucoma surgery (MIGS). The term “MIGS” in Eur...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.